World's Best Scientists 2026 revealed!
Christian Gisselbrecht

Christian Gisselbrecht

D-Index & Metrics

Medicine

D-Index
94
Citations
50407
World Ranking
10261
National Ranking
321

Christian Gisselbrecht publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Christian Gisselbrecht sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 475 publications — 54th percentile

54% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Christian Gisselbrecht D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Christian Gisselbrecht sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 94 D-Index — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Christian Gisselbrecht is affiliated with Université Paris Cité in France and focuses primarily on medical research, with a significant concentration in oncology and hematology.

Their research spans several specialized subfields including pathology and forensic medicine, oncology, hematology, genetics, and molecular biology. Within these areas, the scientist has contributed extensively to topics such as lymphoma diagnosis and treatment, CAR-T cell therapy research, CNS lymphoma diagnosis and treatment, chronic myeloid leukemia treatments, multiple myeloma research and treatments, protein degradation and inhibitors, and acute myeloid leukemia research.

Christian Gisselbrecht has published papers in a variety of scientific journals. Some recent significant publications include:

  • Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma, 2021, Blood Advances
  • A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL, 2020, Blood
  • EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma, 2020, The Oncologist
  • EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma, 2020, The Oncologist
  • Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective, 2020, BMC Cancer

The frequent co-authors who have collaborated with Christian Gisselbrecht include:

  • Francesco Pignatti
  • Harald Enzmann
  • Julio Delgado
  • Michael Crump
  • Norbert Schmitz

The scientist regularly publishes work in several journals, the most frequent being:

  • The Oncologist
  • HemaSphere
  • Blood Advances
  • Blood
  • BMC Cancer

Christian Gisselbrecht's overall contribution to medicine includes 42 publications, with a notable focus on lymphoma and hematological malignancies. Their interdisciplinary expertise covers both clinical treatment evaluation and the biological mechanisms underlying hematological diseases.

Best Publications

  • CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

    Bertrand Coiffier;Eric Lepage;Josette Briere;Raoul Herbrecht

  • A predictive model for aggressive non-Hodgkin's lymphoma

    M. A. Shipp;D. P. Harrington;J. R. Anderson;J. O. Armitage

  • Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma

    T Philip;C Guglielmi;A Hagenbeek;R Somers

  • Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte

    P Feugier;A. Van Hoof;C. Sebban;P. Solal-Celigny

  • Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

    Christian Gisselbrecht;Bertram Glass;Nicolas Mounier;Devinder Singh Gill

  • Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

    Michael Crump;Sattva S. Neelapu;Umar Farooq;Eric Van Den Neste

  • A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

    Eva Hoster;Martin Dreyling;Wolfram Klapper;Christian Gisselbrecht

  • Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

    Georg Hess;Raoul Herbrecht;Jorge Romaguera;Gregor Verhoef

  • Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network

    Martin Dreyling;Georg Lenz;Eva Hoster;Achiel Van Hoof

  • Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

    Nicolas Mounier;Josette Briere;Christian Gisselbrecht;Jean-Francois Emile

  • European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma

    James M. Foran;Ama Z. S. Rohatiner;David Cunningham;Razvan A. Popescu

  • Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study

    Owen A. O'Connor;Barbara Pro;Lauren Pinter-Brown;Nancy Bartlett

  • Prognostic Significance of T-Cell Phenotype in Aggressive Non-Hodgkin's Lymphomas

    Christian Gisselbrecht;Philippe Gaulard;Eric Lepage;Bertrand Coiffier

  • The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells

    Laurence de Leval;David S. Rickman;Caroline Thielen;Aurélien de Reynies

  • Survival Benefit of High-Dose Therapy in Poor-Risk Aggressive Non-Hodgkin’s Lymphoma: Final Analysis of the Prospective LNH87–2 Protocol—A Groupe d’Etude des Lymphomes de l’Adulte Study

    Corinne Haioun;Eric Lepage;Christian Gisselbrecht;Gilles Salles

  • Prognostic significance of survivin expression in diffuse large B-cell lymphomas

    Colette Adida;Corinne Haioun;Philippe Gaulard;Eric Lepage

  • Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.

    Hervé Tilly;Eric Lepage;Bertrand Coiffier;Michel Blanc

  • Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study

    Anjali Advani;Bertrand Coiffier;Myron S. Czuczman;Martin Dreyling

  • Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte.

    C. Haioun;E. Lepage;C. Gisselbrecht;Y. Bastion

  • Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials.

    Nathalie Mourad;Nicolas Mounier;Josette Brière;Emmanuel Raffoux

Frequent Co-Authors

Bertrand Coiffier
Bertrand Coiffier Centre Hospitalier Lyon Sud
Hervé Tilly
Hervé Tilly University of Rouen
Corinne Haioun
Corinne Haioun Paris-Est Créteil University
Philippe Gaulard
Philippe Gaulard Université Paris Cité
Gilles Salles
Gilles Salles Memorial Sloan Kettering Cancer Center
Norbert Schmitz
Norbert Schmitz University of Münster
Raoul Herbrecht
Raoul Herbrecht University of Strasbourg
Massimo Federico
Massimo Federico University of Modena and Reggio Emilia
Martin Dreyling
Martin Dreyling Ludwig-Maximilians-Universität München
Eric D. Hsi
Eric D. Hsi Cleveland Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring a career in Medicine in the USA, you may want to consider related online degrees and alternative healthcare pathways. These options can offer more flexibility, lower tuition, and diverse career opportunities. Many students opt for programs such as a HIM degree online to gain expertise in health data management. With the healthcare field’s growing reliance on digital records, this role is in high demand.

Another popular option is pursuing medical billing and coding. The medical coding certification cost is generally much lower than full medical degrees, while still offering promising job prospects in administrative healthcare settings.

For those interested in advanced nursing roles, you might explore the cheapest online acute care nurse practitioner programs or look for affordable nursing programs online. These pathways allow you to make a significant impact on patient care, all while benefiting from the convenience and affordability of remote study.

Best Scientists Citing Christian Gisselbrecht

Trending Scientists

Recently Published Articles